Eli Lilly and Company (LLY.US) Q1 2026 Earnings Conference Call
Live time: Apr 30, 2026 14:00 UTC
Eli Lilly and Company (LLY.US) Q1 2026 Earnings Conference Call
Live time: 04/30/2026 14:00:00 UTC
礼来公司 (LLY.US) 2026 年第一季度业绩电话会
Summary
00:56
Opening Remarks by Mike Zapar
Mike Zapar, Senior Vice President of Investor Relations, opened Eli Lilly's Q1 2026 earnings call, introduced key executives, and discussed the agenda, including forward-looking statements and non-GAAP financial metrics.
02:50
CEO Dave Ricks Q1 Business Overview
CEO Dave Ricks announced robust revenue growth for Q1 2026, significant R&D pipeline progress across four therapeutic areas, and the approval of PRIMEEO by the US FDA for weight management, marking it as a milestone for Eli Lilly.
05:24
Q1 Financial Results Overview by CFO Lucas Montarsay
CFO Lucas Montarsay highlighted strong Q1 financial performance with a 56% increase in revenue compared to Q1 2025, and a non-GAAP EPS of $8.55 benefiting from revenue growth and ongoing R&D investments.
17:30
R&D Developments by Dan Skorowski
Dan Skorowski, Chief Science and Practice Officer, revealed new achievements in Eli Lilly’s pipeline, including cardiovascular advances, Fondeo's clinical success, and six new Phase 3 programs in obesity and related illnesses.
30:00
Q&A Session Introduction by Mike Zapar
Mike Zapar commenced the Q&A session, inviting analysts to ask focused single questions to maximize participant interaction time.
30:55
Pricing and Profit Margin Discussion — Analyst: Geoff Meacham (Citi)
CEO Dave Ricks discussed pricing dynamics, addressing investor concerns on pricing sensitivity across geographies and emphasizing cost structure scalability as key drivers for profitability.
34:23
International Growth of Monjaro — Analyst: Chris Schott (Morgan J.P.)
Patrick Gondin described Monjaro's rapid uptake in over 55 countries with accelerated market penetration and strong competitive resilience against generic alternatives.
40:38
Medicare Expansion Strategy — Analyst: Alex Hammond (Wolfe Research)
Ilya Juffa outlined strategies for Medicare Part D launches, emphasizing sustained growth through consumer education, provider engagement, and affordability measures such as $50 monthly out-of-pocket costs.
44:55
Early FONDEO Launch Feedback — Analyst: Hassad (DB)
Ilya Juffa shared early insights from FONDEO's launch, with over 20,000 patients onboard and strong initial feedback emphasizing convenience and clinical efficacy.
1:04:30
Employer Insurance Outlook — Analyst: Dave Risinger (Leerink Partners)
Dave Ricks discussed the role of commercial insurance and direct employer plans in expanding coverage for obesity, projecting gradual adoption driven by regulatory frameworks and real-world evidence for cost-effectiveness.
Related Notices
Recent Live Streams
Eli Lilly and Company (LLY.US) Q3 2026 Earnings Call
Live Assistant
Eli Lilly and Company (LLY.US) Q2 2026 Earnings Conference Call
Live Assistant
Eli Lilly and Company (LLY.US) Q4 2025 Earnings Conference Call
Live Assistant
Eli Lilly and Company (LLY.US) Q3 2025 Earnings Conference Call
Live Assistant
Risk Disclaimer: The content on this page represents the author's personal opinions for general information purposes only and should not be used as a basis for any specific investment, business or commercial decision. It does not represent the position of Longbridge, and the platform makes no guarantees or commitments regarding the authenticity, accuracy or originality of the above content.